No data to show
XASX
ACL
Market cap354mUSD
Jul 11, Last price
2.76AUD
1D
0.00%
1Q
-7.07%
IPO
-19.30%
Name
Australian Clinical Labs Ltd
Chart & Performance
P/E
22.48
P/S
0.78
EPS
0.12
Div Yield, %
4.35%
Shrs. gr., 5y
-0.28%
Rev. gr., 5y
9.12%
Revenues
690m
-0.34%
Net income
24m
-33.33%
CFO
160m
+11.07%
Dividend
Sep 04, 20240.09 AUD/sh
Earnings
Aug 27, 2025
Profile
Australian Clinical Labs Limited provides pathology services in Australia. The company offers range of services, which include routine pathology test, advanced molecular genetics testing, harmony NIPT and first trimester screening, genetic carrier screening, chemical pathology, histopathology, and cytopathology; hematology, allergy, and immunology; serology and microbiology; and infectious molecular testing, cardiac testing services, functional pathology, veterinary pathology, and commercial drug and alcohol testing services. It offers its service to private and public hospitals. The company was incorporated in 2020 and is headquartered in Clayton, Australia.
IPO date
May 14, 2021
Employees
5,115
Domiciled in
AU
Incorporated in
AU
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||
Revenues | 689,728 -0.34% | 692,103 -30.04% | ||||||
Cost of revenue | 529,561 | 423,477 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | 160,167 | 268,626 | ||||||
NOPBT Margin | 23.22% | 38.81% | ||||||
Operating Taxes | 12,122 | 12,268 | ||||||
Tax Rate | 7.57% | 4.57% | ||||||
NOPAT | 148,045 | 256,358 | ||||||
Net income | 23,934 -33.33% | 35,901 -79.86% | ||||||
Dividends | (19,949) | (96,880) | ||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | (1,742) | (891) | ||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | 104,709 | 32,348 | ||||||
Long-term debt | 458,025 | 465,857 | ||||||
Deferred revenue | ||||||||
Other long-term liabilities | 3,402 | 3,083 | ||||||
Net debt | 535,889 | 478,250 | ||||||
| Cash flow | ||||||||
Cash from operating activities | 159,592 | 143,681 | ||||||
CAPEX | (6,505) | (6,934) | ||||||
Cash from investing activities | (7,247) | (12,182) | ||||||
Cash from financing activities | (146,139) | (137,876) | ||||||
FCF | 156,321 | 269,580 | ||||||
| Balance | ||||||||
Cash | 26,845 | 19,955 | ||||||
Long term investments | 1 | |||||||
Excess cash | ||||||||
Stockholders' equity | 177,765 | 172,671 | ||||||
Invested Capital | 490,066 | 492,073 | ||||||
ROIC | 30.15% | 52.10% | ||||||
ROCE | 32.68% | 54.59% | ||||||
| EV | ||||||||
Common stock shares outstanding | 199,472 | 201,116 | ||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | 288,594 | 391,381 | ||||||
EV/EBITDA | ||||||||
Interest | 17,040 | 3,540 | ||||||
Interest/NOPBT | 10.64% | 1.32% | ||||||